Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2020 16:07 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280
November 02, 2020 08:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
October 29, 2020 07:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference
October 07, 2020 08:08 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020 07:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer
September 24, 2020 07:00 ET | Calithera Biosciences, Inc.
- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting among patients with non-small cell lung cancer and a mutation...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera to Participate in Multiple Upcoming Investor Conferences
September 04, 2020 07:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2020 07:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
August 10, 2020 16:06 ET | Calithera Biosciences, Inc.
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences,...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2020 07:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...